EMSELEX 15mg prolonged-release tablets MERUS LABS LUXCO II
darifenacin Indicated for: overactive bladder; urinary incontinence
letter E · page 15
darifenacin Indicated for: overactive bladder; urinary incontinence
darifenacin Indicated for: overactive bladder; urinary incontinence
methotrexate Indicated for: cancer; autoimmune inflammatory diseases
L01BA01 Antineoplastic and immunomodulating agents | Antimetabolites | Folic acid analogues
emtricitabine + tenofovir alafenamide Indicated for: HIV-1 infection
emtricitabine + tenofovir alafenamide Indicated for: HIV-1 infection
emtricitabine + tenofovir disoproxil Indicated for: HIV-1 infection
emtricitabine + tenofovir Indicated for: HIV-1 infection
emtricitabine + tenofovir disoproxil Indicated for: HIV-1 infection
emtricitabine + tenofovir disoproxil Indicated for: HIV-1 infection
emtricitabine + tenofovir disoproxil Indicated for: HIV-1 infection
emtricitabine + tenofovir disoproxil Indicated for: HIV-1 infection
emtricitabine + tenofovir disoproxil Indicated for: HIV-1 infection
emtricitabine + tenofovir disoproxil Indicated for: HIV-1 infection
emtricitabine + tenofovir disoproxil Indicated for: HIV-1 infection
emtricitabine Indicated for: HIV-1 infection
emtricitabine Indicated for: HIV-1 infection
pramipexole Indicated for: Parkinson's disease
N04BC05 Nervous system | Dopaminergic agents | Dopamine agonists
pramipexole Indicated for: Parkinson's disease
N04BC05 Nervous system | Dopaminergic agents | Dopamine agonists
pramipexole Indicated for: Parkinson's disease
N04BC05 Nervous system | Dopaminergic agents | Dopamine agonists
metoprolol Indicated for: hypertension; angina pectoris